Evaluation of a targeted next-generation sequencing–based CYP2D6 genotyping method compared with Sanger sequencing and multiplex ligation-dependent probe amplification
Laboratory Medicine · 08.09.2025 · 56 (5) · 454-459
DOI: 10.1093/labmed/lmae115 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Laboratory Medicine, online erschienen am 26.03.2025. Verfasst von Won-Kyu Choi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea. Hauptthemen laut MEDLINE: Genotyping Techniques, Pharmacogenomic Testing, High-Throughput Nucleotide Sequencing, Cytochrome P-450 CYP2D6. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben.
Abstract (Originalsprache)
Introduction
CYP2D6 genotyping can guide the appropriate prescription of related drugs, but its complex genetic alterations make clinical implementation challenging. In this study, we evaluated the performance of a custom-made, targeted next-generation sequencing (NGS)–based CYP2D6 genotyping method by comparing it with Sanger sequencing and multiplex ligation-dependent probe amplification (MLPA) methods.
Methods
CYP2D6 was included in a customized NGS multigene panel. CYP2D6 genotypes were analyzed in 91 patients, including copy number variations (CNV) analysis based on read depth. For comparison, single-nucleotide variations (formerly single-nucleotide polymorphisms) and CNVs were assessed using Sanger sequencing and MLPA, and the genotype was determined. Differences in genotype and predicted phenotype according to these 2 approaches were evaluated.
Results
The NGS-based results were 100% concordant in single-nucleotide variations compared with Sanger sequencing, but 4 cases (4.4%) were discordant in CNVs with MLPA. Consequently, the NGS-based genotype was 95.6% concordant with the combined Sanger sequencing and MLPA approach. However, the classification of the predicted phenotype was unchanged in the 4 cases with differing assigned genotypes.
Discussion
The NGS-based CYP2D6 genotyping method showed good performance, suggesting its potential utility in clinical practice. Including CYP2D6 in an NGS panel for patients who may use drugs metabolized by CYP2D6 may provide additional useful information.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea.
- Department of Laboratory Medicine, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, Korea.
Zitieren
APA
Choi, W. K., Kim, H. K., Kim, S., Lee, W., & Chun, S. (2025). Evaluation of a targeted next-generation sequencing–based CYP2D6 genotyping method compared with Sanger sequencing and multiplex ligation-dependent probe amplification. Laboratory Medicine, 56(5), 454-459. https://doi.org/10.1093/labmed/lmae115
Vancouver
Choi WK, Kim HK, Kim S, Lee W, Chun S. Evaluation of a targeted next-generation sequencing–based CYP2D6 genotyping method compared with Sanger sequencing and multiplex ligation-dependent probe amplification. Laboratory Medicine. 2025;56(5):454-459. doi:10.1093/labmed/lmae115
BibTeX
@article{Choi2025,
author = {Choi, Won-Kyu and Kim, Hyun-Ki and Kim, Sollip and Lee, Woochang and Chun, Sail},
title = {Evaluation of a targeted next-generation sequencing–based CYP2D6 genotyping method compared with Sanger sequencing and multiplex ligation-dependent probe amplification},
journal = {Laboratory Medicine},
year = {2025},
volume = {56},
number = {5},
pages = {454--459},
doi = {10.1093/labmed/lmae115}
}
EUVIMED